Literature DB >> 11676500

Amino acid sequence requirements of peptides that inhibit polyglutamine-protein aggregation and cell death.

H Ren1, Y Nagai, T Tucker, W J Strittmatter, J R Burke.   

Abstract

Proteins with expanded polyglutamine domains cause eight inherited neurodegenerative diseases including Huntington's disease. In a previous paper, we identified peptides that inhibit polyglutamine protein aggregation and cell death and now describe the amino acid sequence requirements necessary for these activities. The original 11 amino acid polyglutamine (Q) Binding Peptide 1(QBP1; SNWKWWPGIFD) can be shortened to 8 amino acids (WKWWPGIF) without loss of ability to inhibit polyglutamine aggregation. Three determinants are responsible for inhibition: a tryptophan-rich motif (WKWW), a spacer amino acid and the tripeptide GIF. GIF can be replaced by a repeat of the tryptophan-rich motif, but the spacer remains necessary. We also demonstrate concordance between peptide activity in the in vitro assay and a cellular assay of polyglutamine aggregation and cell death. Polyglutamine binding peptides targeted for intracellular delivery by fusion to TAT retain the ability to inhibit polyglutamine aggregation and cell death in transfected COS 7 cells. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11676500     DOI: 10.1006/bbrc.2001.5783

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

Review 1.  Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins.

Authors:  David C Butler; Julie A McLear; Anne Messer
Journal:  Prog Neurobiol       Date:  2011-11-18       Impact factor: 11.685

2.  Characterization of a possible amyloidogenic precursor in glutamine-repeat neurodegenerative diseases.

Authors:  Roger S Armen; Brady M Bernard; Ryan Day; Darwin O V Alonso; Valerie Daggett
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-12       Impact factor: 11.205

3.  Modified single-stranded oligonucleotides inhibit aggregate formation and toxicity induced by expanded polyglutamine.

Authors:  Hetal Parekh-Olmedo; Jin Wang; James F Gusella; Eric B Kmiec
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

4.  Two-dimensional infrared correlation spectroscopy study of sequential events in the heat-induced unfolding and aggregation process of myoglobin.

Authors:  Yong-Bin Yan; Qi Wang; Hua-Wei He; Xin-Yao Hu; Ri-Qing Zhang; Hai-Meng Zhou
Journal:  Biophys J       Date:  2003-09       Impact factor: 4.033

Review 5.  Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases.

Authors:  H Akiko Popiel; Toshihide Takeuchi; James R Burke; Warren J Strittmatter; Tatsushi Toda; Keiji Wada; Yoshitaka Nagai
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

6.  The Aggregation Inhibitor Peptide QBP1 as a Therapeutic Molecule for the Polyglutamine Neurodegenerative Diseases.

Authors:  H Akiko Popiel; James R Burke; Warren J Strittmatter; Shinya Oishi; Nobutaka Fujii; Toshihide Takeuchi; Tatsushi Toda; Keiji Wada; Yoshitaka Nagai
Journal:  J Amino Acids       Date:  2011-06-30

7.  DNAJB6 is a peptide-binding chaperone which can suppress amyloid fibrillation of polyglutamine peptides at substoichiometric molar ratios.

Authors:  Cecilia Månsson; Vaishali Kakkar; Elodie Monsellier; Yannick Sourigues; Johan Härmark; Harm H Kampinga; Ronald Melki; Cecilia Emanuelsson
Journal:  Cell Stress Chaperones       Date:  2013-08-01       Impact factor: 3.667

Review 8.  Protein Aggregation Inhibitors as Disease-Modifying Therapies for Polyglutamine Diseases.

Authors:  Eiko N Minakawa; Yoshitaka Nagai
Journal:  Front Neurosci       Date:  2021-02-12       Impact factor: 4.677

Review 9.  Protein Misfolding and Aggregation as a Therapeutic Target for Polyglutamine Diseases.

Authors:  Toshihide Takeuchi; Yoshitaka Nagai
Journal:  Brain Sci       Date:  2017-10-11

10.  Identification of a novel site of interaction between ataxin-3 and the amyloid aggregation inhibitor polyglutamine binding peptide 1.

Authors:  Patrick D Knight; Theodoros K Karamanos; Sheena E Radford; Alison E Ashcroft
Journal:  Eur J Mass Spectrom (Chichester)       Date:  2017-08-29       Impact factor: 1.067

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.